Diagnosis and Treatment of Monogenic Hypertension in Children

키워드

참고문헌 (65)

1. Flynn JT, "Clinical practice guideline for screening and management of high blood pressure in children and adolescents", Pediatrics, 140, pp.e20171904~ (2017)
2. Lurbe E, "2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents", J Hypertens, 34, pp.1887~1920 (2016)
3. Wühl E, "Hypertension in childhood obesity", Acta Paediatr, 108, pp.37~43 (2019)
4. Mozaffarian D, "Heart disease and stroke statistics--2015 update : a report from the American Heart Association", Circulation, 131, pp.e29~e322 (2015)
5. Rademacher ER, "Relation of blood pressure and body mass index during childhood to cardiovascular risk factor levels in young adults", J Hypertens, 27, pp.1766~1774 (2009)
6. Frohlich ED, "Irvine H. Page : 1901-1991. The celebration of a leader", Hypertension, 18, pp.443~445 (1991)
7. Havlik RJ, "Blood pressure aggregation in families", Am J Epidemiol, 110, pp.304~312 (1979)
8. Bonati MT, "Heritability of blood pressure through latent curve trajectories in families from the Gubbio population study", J Hypertens, 32, pp.2179~2187 (2014)
9. Lifton RP, "Molecular mechanisms of human hypertension", Cell, 104, pp.545~556 (2001)
10. Padmanabhan S, "Genetic and molecular aspects of hypertension", Circ Res, 116, pp.937~959 (2015)
11. Ahn SY, "Genetic programming of hypertension", Front Pediatr, 5, pp.285~ (2018)
12. Vehaskari VM, "Heritable forms of hypertension", Pediatr Nephrol, 24, pp.1929~1937 (2009)
13. Garovic VD, "Monogenic forms of low-renin hypertension", Nat Clin Pract Nephrol, 2, pp.624~630 (2006)
14. Vaidya A, "Genetics of primary aldosteronism", Endocr Pract, 21, pp.400~405 (2015)
15. Zennaro MC, "Genetic causes of functional adrenocortical adenomas", Endocr Rev, 38, pp.516~537 (2017)
16. Levanovich PE, "Clinical and molecular perspectives of monogenic hypertension", Curr Hypertens Rev, 16, pp.91~107 (2020)
17. Fisher A, "Effects of 18-hydroxylated steroids on corticosteroid production by human aldosterone synthase and 11beta-hydroxylase", J Clin Endocrinol Metab, 86, pp.4326~4329 (2001)
18. Montori VM, "Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature", Endocrinol Metab Clin North Am, 31, pp.619~632 (2002)
19. Gates LJ, "Is random screening of value in detecting glucocorticoid-remediable aldosteronism within a hypertensive population?", J Hum Hypertens, 15, pp.173~176 (2001)
20. Litchfield WR, "Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism", Hypertension, 31(1 Pt 2), pp.445~450 (1998)
21. Funder JW, "The management of primary aldosteronism : case detection, diagnosis, and treatment : an endocrine society clinical practice guideline", J Clin Endocrinol Metab, 101, pp.1889~1916 (2016)
22. Baudrand R, "The low-renin hypertension phenotype : genetics and the role of the mineralocorticoid receptor", Int J Mol Sci, 19, pp.546~ (2018)
23. Hundemer GL, "Cardiometabolic outcomes and mortality in medically treated primary aldosteronism : a retrospective cohort study", Lancet Diabetes Endocrinol, 6, pp.51~59 (2018)
24. Scholl UI, "CLCN2 chloride channel mutations in familial hyperaldosteronism type II", Nat Genet, 50, pp.349~354 (2018)
25. Stowasser M, "Primary aldosteronism--careful investigation is essential and rewarding", Mol Cell Endocrinol, 217, pp.33~39 (2004)
26. Korah HE, "An update on familial hyperaldosteronism", Horm Metab Res, 47, pp.941~946 (2015)
27. Burrello J, "Is there a role for genomics in the management of hypertension?", Int J Mol Sci, 18, pp.1131~ (2017)
28. Geller DS, "A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism", J Clin Endocrinol Metab, 93, pp.3117~3123 (2008)
29. Choi M, "K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension", Science, 331, pp.768~772 (2011)
30. Scholl UI, "Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism", Elife, 4, pp.e06315~ (2015)
31. Daniil G, "CACNA1H mutations are associated with different forms of primary aldosteronism", EBioMedicine, 13, pp.225~236 (2016)
32. Fernandes-Rosa FL, "Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma", Hypertension, 64, pp.354~361 (2014)
33. Monticone S, "Understanding primary aldosteronism : impact of next generation sequencing and expression profiling", Mol Cell Endocrinol, 399, pp.311~320 (2015)
34. Simonetti GD, "Monogenic forms of hypertension", Eur J Pediatr, 171, pp.1433~1439 (2012)
35. Portrat S, "Deletion hybrid genes, due to unequal crossing over between CYP11B1(11beta-hydroxylase)and CYP11B2(aldosterone synthase)cause steroid 11beta-hydroxylase deficiency and congenital adrenal hyperplasia", J Clin Endocrinol Metab, 86, pp.3197~3201 (2001)
36. Yau M, "Clinical, genetic, and structural basis of apparent mineralocorticoid excess due to 11β-hydroxysteroid dehydrogenase type 2 deficiency", Proc Natl Acad Sci U S A, 114, pp.E11248~E11256 (2017)
37. Taninee Sahakitrungruang, "Clinical and molecular review of atypical congenital adrenal hyperplasia", Annals of Pediatric Endocrinology & Metabolism, 20(1), pp.1~7 (2015), 대한소아내분비학회
38. Yang N, "Current concepts in glucocorticoid resistance", Steroids, 77, pp.1041~1049 (2012)
39. Vitellius G, "Three novel heterozygous point mutations of NR3C1 causing glucocorticoid resistance", Hum Mutat, 37, pp.794~803 (2016)
40. van Rossum EF, "Glucocorticoid resistance syndrome : a diagnostic and therapeutic approach", Best Pract Res Clin Endocrinol Metab, 20, pp.611~626 (2006)
41. Wilson FH, "Human hypertension caused by mutations in WNK kinases", Science, 293, pp.1107~1112 (2001)
42. Boyden LM, "Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities", Nature, 482, pp.98~102 (2012)
43. Gordon RD, "Syndrome of hypertension and hyperkalemia with normal glomerular filtration rate", Hypertension, 8, pp.93~102 (1986)
44. Murthy M, "WNK signalling pathways in blood pressure regulation", Cell Mol Life Sci, 74, pp.1261~1280 (2017)
45. Liddle GW, "A familial renal disorder simulating primary aldosteronism but with negligible aldosterone secretion", Trans Assoc Am Phys, 76, pp.199~213 (1963)
46. Hansson JH, "Hypertension caused by a truncated epithelial sodium channel gamma subunit : genetic heterogeneity of Liddle syndrome", Nat Genet, 11, pp.76~82 (1995)
47. Snyder PM, "Mechanism by which Liddle’s syndrome mutations increase activity of a human epithelial Na+ channel", Cell, 83, pp.969~978 (1995)
48. Salih M, "A missense mutation in the extracellular domain of αENaC causes Liddle syndrome", J Am Soc Nephrol, 28, pp.3291~3299 (2017)
49. Monnens L, "Distinction between Liddle syndrome and apparent mineralocorticoid excess", Pediatr Nephrol, 19, pp.118~119 (2004)
50. Nesterov V, "In Liddle syndrome, epithelial sodium channel is hyperactive mainly in the early part of the aldosterone-sensitive distal nephron", Hypertension, 67, pp.1256~1262 (2016)
51. Akintunde A, "Physiological phenotyping for personalized therapy of uncontrolled hypertension in Africa", Am J Hypertens, 30, pp.923~930 (2017)
52. Lifton RP, "The molecular basis of a hereditary form of hypertension, glucocorticoid-remediable aldosteronism", Trends Endocrinol Metab, 4, pp.57~61 (1993)
53. Dave-Sharma S, "Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess", J Clin Endocrinol Metab, 83, pp.2244~2254 (1998)
54. New MI, "Steroid disorders in children : congenital adrenal hyperplasia and apparent mineralocorticoid excess", Proc Natl Acad Sci U S A, 96, pp.12790~12797 (1999)
55. Ulick S, "A new form of the syndrome of apparent mineralocorticoid excess", J Steroid Biochem, 32, pp.209~212 (1989)
56. Campino C, "Age-related changes in 11β-hydroxysteroid dehydrogenase type 2 activity in normotensive subjects", Am J Hypertens, 26, pp.481~487 (2013)
57. Sabbadin C, "Syndromes that mimic an excess of mineralocorticoids", High Blood Press Cardiovasc Prev, 23, pp.231~235 (2016)
58. Geller DS, "Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy", Science, 289, pp.119~123 (2000)
59. Lu YT, "Overview of monogenic forms of hypertension combined with hypokalemia", Front Pediatr, 8, pp.543309~ (2021)
60. Moras D, "The nuclear receptor ligand-binding domain : structure and function", Curr Opin Cell Biol, 10, pp.384~391 (1998)
61. Rafestin-Oblin ME, "The severe form of hypertension caused by the activating S810L mutation in the mineralocorticoid receptor is cortisone related", Endocrinology, 144, pp.528~533 (2003)
62. Padmanabhan S, "Genomics of hypertension : the road to precision medicine", Nat Rev Cardiol, 18, pp.235~250 (2021)
63. Molnár Á, "An unexpected, mild phenotype of glucocorticoid resistance associated with glucocorticoid receptor gene mutation case report and review of the literature", BMC Med Genet, 19, pp.37~ (2018)
64. Stowasser M, "Pathogenesis of familial hyperaldosteronism type II : new concepts involving anion channels", Curr Hypertens Rep, 21, pp.31~ (2019)
65. Raina R, "Overview of monogenic or mendelian forms of hypertension", Front Pediatr, 7, pp.263~ (2019)

관련 논문AI추천